All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with low cardiac output syndrome
It is very uncertain whether enoximone changes all‐cause short‐term mortality: 1 month compared with dobutamine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · preterm or very low birth weight infants
It is very uncertain whether summary of findings table ‐ Silicone earplugs changes all‐cause mortality during hospital stay compared with no earplugs (very low certainty).
1 finding from 1 review
All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality within 30 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes all‐cause mortality within 30 days of surgery compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
All‐cause mortality ( · adult patients with an implantable cardioverter defibrillator
It is very uncertain whether exercise changes all‐cause mortality ( compared with no exercise at longest available follow‐up (very low certainty).
1 finding from 1 review
Mortality before hospital discharge · very preterm or very low birth weight infants
1 finding from 1 review
Mortality before hospital discharge · extremely preterm or extremely low birth weight infants
1 finding from 1 review
Mortality before hospital discharge · very preterm or very low birth weight infants
1 finding from 1 review
Mortality before hospital discharge · very preterm or very low birth weight infants
1 finding from 1 review
Mortality before hospital discharge · exclusively formula‐fed preterm or low birth weight infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: time in hospital · adults with low cardiac output syndrome
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
1 finding from 1 review
All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).
1 finding from 1 review